The broad spectrum of cancer and immunotherapy: achievements and limitations

Cancer immunotherapy has revolutionized cancer treatment over the past decades, offering renewed hope to patients with previously untreatable malignancies. This therapeutic approach could be categorized into three primary strategies: immune checkpoint blockade, adoptive cell therapy, and cancer vaccines. Immune checkpoint inhibitors have been highly successful in boosting anti-tumour immune responses by blocking the immunosuppressive signals that cancer cells exploit to evade immune surveillance, mainly that exerted by cytotoxic T lymphocytes. Adoptive cell therapy, particularly chimeric antigen receptor (CAR)-T cell therapy, involves the infusion of genetically modified cytotoxic T cells to specifically target tumour cells, showing particular efficacy in hematological malignancies. Cancer vaccines have also emerged as a promising strategy, eliciting anti-tumour responses via the patient’s own immune system. Despite these advancements, several challenges persist, particularly in the treatment of solid tumours. These include the development of tumour resistance, off-target effects that lead to adverse side effects, manufacturing complications, and variability in patient clinical outcomes. Overcoming these limitations will require further research and innovation to optimize the clinical translation of immunotherapy and broaden its application toward more personalized medicine. This review highlights the advancements and key challenges in the mentioned cancer immunotherapy strategies, with a special emphasis on the reinforcement of adaptive immune system against tumour cells. Additionally, some alternative approaches relying on the modulation of innate immune system are also summarized.

• Publication year

  2026

• Venue

  Frontiers in Immunology

• Publication date

  2026-01-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2025.1697505PMID 41601679PMCID 12833403
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration

  2025cited by this paper
• Improved Efficacy of Triple‐Negative Breast Cancer Immunotherapy via Hydrogel‐Based Co‐Delivery of CAR‐T Cells and Mitophagy Agonist

  2025cited by this paper
• First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

  2025cited by this paper
• Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.

  2025cited by this paper
• Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer.

  2025cited by this paper
• Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.

  2025cited by this paper
• From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies

  2025cited by this paper
• The potential application of stroma modulation in targeting tumor cells: focus on pancreatic cancer and breast cancer models.

  2025cited by this paper
• Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy

  2025cited by this paper
• CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models

  2025cited by this paper
• RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

  2025cited by this paper
• Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma

  2025cited by this paper
• CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

  2025cited by this paper
• CAR T CELL THERAPY

  2024cited by this paper
• Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

  2024cited by this paper
• CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

  2024cited by this paper
• Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound

  2024cited by this paper
• IGSF8 is an innate immune checkpoint and cancer immunotherapy target.

  2024cited by this paper
• Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization

  2024cited by this paper
• Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

  2024cited by this paper
• Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system

  2024cited by this paper
• Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations

  2024cited by this paper
• Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma

  2024cited by this paper
• Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy

  2024cited by this paper
• Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy

  2024cited by this paper
• Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

  2024cited by this paper
• The functional role of L-fucose on dendritic cell function and polarization

  2024cited by this paper
• Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer

  2024cited by this paper
• Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

  2024cited by this paper
• Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy

  2024cited by this paper
• Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients

  2024cited by this paper
• EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Upregulation of CD47.

  2024cited by this paper
• Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

  2024cited by this paper
• Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice

  2024cited by this paper
• High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

  2024cited by this paper
• Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumor microenvironment and its implications for immune-related prognosis

  2024cited by this paper
• Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

  2024cited by this paper
• CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.

  2024cited by this paper
• Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors

  2024cited by this paper
• Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives

  2024cited by this paper
• Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines

  2024cited by this paper
• Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma.

  2024cited by this paper
• Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer

  2024cited by this paper
• Pan-cancer proteogenomics characterization of tumor immunity

  2024cited by this paper
• Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

  2024cited by this paper
• Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer

  2024cited by this paper
• rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells

  2024cited by this paper
• A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

  2024cited by this paper
• Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors

  2024cited by this paper
• Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.

  2024cited by this paper
• Current status and future of cancer vaccines: A bibliographic study

  2024cited by this paper
• Neoantigen‐Displaying Protein Nanoparticles as a Therapeutic Cancer Vaccine Against Melanoma

  2024cited by this paper
• CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases

  2024cited by this paper
• CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws

  2024cited by this paper
• Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer

  2024cited by this paper
• AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1/PD-L1 Axis in the Tumor Microenvironment

  2024cited by this paper
• Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

  2024cited by this paper
• Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy

  2024cited by this paper
• Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells

  2024cited by this paper
• Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome

  2024cited by this paper
• First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study

  2024cited by this paper
• TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors

  2024cited by this paper
• The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy.

  2024cited by this paper
• TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors

  2023cited by this paper
• circRNA-SMO upregulates CEP85 to promote proliferation and migration of glioblastoma via sponging miR-326.

  2023cited by this paper
• Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia

  2023cited by this paper
• Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials

  2023cited by this paper
• The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors

  2023cited by this paper
• Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles

  2023cited by this paper
• Decreased survival in patients with pancreatic cancer may be associated with an increase in histopathological expression of inflammasome marker NLRP3.

  2023cited by this paper
• The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review

  2023cited by this paper
• RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells

  2023cited by this paper
• Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours

  2023cited by this paper
• Advanced Oxidation Nanoprocessing Boosts Immunogenicity of Whole Tumor Cells

  2023cited by this paper
• Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells

  2023cited by this paper
• A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma

  2023cited by this paper
• B-cell-specific checkpoint molecules that regulate anti-tumour immunity

  2023cited by this paper
• A Multivalent Personalized Vaccine Orchestrating Two‐Signal Activation Rebuilds the Bridge Between Innate and Adaptive Antitumor Immunity

  2023cited by this paper
• Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination.

  2023cited by this paper
• Adoptive cell therapy for cancer treatment

  2023cited by this paper
• Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness

  2023cited by this paper
• rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses

  2023cited by this paper
• A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

  2023cited by this paper
• A membrane-associated MHC-I inhibitory axis for cancer immune evasion.

  2023cited by this paper
• Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis

  2023cited by this paper
• Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review

  2023cited by this paper
• RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial

  2023cited by this paper
• Tumor microenvironment and CAR‐T cell immunotherapy in B‐cell lymphoma

  2023cited by this paper
• A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma

  2023cited by this paper
• Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report

  2023cited by this paper
• Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach

  2023cited by this paper
• Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

  2023cited by this paper
• Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns

  2023cited by this paper
• CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

  2023cited by this paper
• CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

  2023cited by this paper
• Characterization of the genomic alterations in poorly differentiated thyroid cancer

  2023cited by this paper
• A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis

  2023cited by this paper
• Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.

  2023cited by this paper
• Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy

  2023cited by this paper
• Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

  2023cited by this paper

• No citing papers are available for this paper.